DK2970132T3 - Argininmethyltransferaseinhibitorer og anvendelser deraf - Google Patents
Argininmethyltransferaseinhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK2970132T3 DK2970132T3 DK14717371.0T DK14717371T DK2970132T3 DK 2970132 T3 DK2970132 T3 DK 2970132T3 DK 14717371 T DK14717371 T DK 14717371T DK 2970132 T3 DK2970132 T3 DK 2970132T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyltransferase inhibitors
- arginine methyltransferase
- arginine
- inhibitors
- methyltransferase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361781051P | 2013-03-14 | 2013-03-14 | |
US201361876034P | 2013-09-10 | 2013-09-10 | |
PCT/US2014/029710 WO2014153226A1 (en) | 2013-03-14 | 2014-03-14 | Arginine methyltransferase inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2970132T3 true DK2970132T3 (da) | 2020-12-21 |
Family
ID=50483598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14717371.0T DK2970132T3 (da) | 2013-03-14 | 2014-03-14 | Argininmethyltransferaseinhibitorer og anvendelser deraf |
Country Status (25)
Country | Link |
---|---|
US (5) | US9598374B2 (da) |
EP (1) | EP2970132B1 (da) |
JP (1) | JP6581076B2 (da) |
KR (2) | KR102158756B1 (da) |
CN (2) | CN105339351B (da) |
AU (2) | AU2014236146B2 (da) |
BR (1) | BR112015022785A2 (da) |
CA (1) | CA2903394C (da) |
CY (1) | CY1123637T1 (da) |
DK (1) | DK2970132T3 (da) |
EA (1) | EA030481B1 (da) |
ES (1) | ES2837034T3 (da) |
HK (1) | HK1219736A1 (da) |
HR (1) | HRP20202008T1 (da) |
HU (1) | HUE052926T2 (da) |
IL (2) | IL241368B (da) |
LT (1) | LT2970132T (da) |
MX (1) | MX2015012850A (da) |
PL (1) | PL2970132T3 (da) |
PT (1) | PT2970132T (da) |
RS (1) | RS61231B1 (da) |
SG (1) | SG11201506972PA (da) |
SI (1) | SI2970132T1 (da) |
WO (1) | WO2014153226A1 (da) |
ZA (1) | ZA201507441B (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
EP2935243B1 (en) | 2012-12-21 | 2018-03-14 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970136A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153090A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives asprmt1 inhibitors and uses thereof |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
KR102158756B1 (ko) | 2013-03-14 | 2020-09-23 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
WO2014178954A1 (en) | 2013-03-14 | 2014-11-06 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
EA201591532A1 (ru) | 2013-03-15 | 2016-03-31 | Эпизим, Инк. | Ингибиторы carm1 и их применение |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2016044576A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
BR112019011370A2 (pt) * | 2016-12-01 | 2019-10-15 | Glaxosmithkline Ip Dev Ltd | terapia de combinação |
EP3548638A1 (en) * | 2016-12-01 | 2019-10-09 | GlaxoSmithKline Intellectual Property Development Limited | Methods of treating cancer |
KR20190090821A (ko) * | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 조합 요법 |
BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
US20210260033A1 (en) * | 2018-05-31 | 2021-08-26 | Glaxosmithkline Intellectual Property Development Limited | Combined therapy with icos binding proteins and argininemethyltransferase inhibitors |
WO2020182018A1 (zh) * | 2019-03-12 | 2020-09-17 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
KR20220023330A (ko) * | 2019-03-25 | 2022-03-02 | 캘리포니아 인스티튜트 오브 테크놀로지 | Prmt5 억제제 및 이의 용도 |
WO2021023609A1 (en) * | 2019-08-02 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor |
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
KR102219251B1 (ko) | 2020-03-03 | 2021-02-22 | 김명수 | 전문가 추천 플랫폼을 제공하는 서버 및 그 운용방법 |
CN111481532B (zh) * | 2020-06-28 | 2020-09-22 | 南京中澳转化医学研究院有限公司 | 化合物28d在制备提高γ-珠蛋白表达量的药物中的应用 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085859B2 (ja) | 1986-07-01 | 1996-01-24 | 日本バイエルアグロケム株式会社 | 新規アルキレンジアミン類 |
EP0352581A3 (de) | 1988-07-28 | 1990-07-04 | F. Hoffmann-La Roche Ag | Aethylendiaminmonoamid-Derivate |
US5204482A (en) | 1988-07-28 | 1993-04-20 | Hoffman-Laroche Inc. | Compounds for treating and preventing cognitive diseases and depression and methods of making same |
AU3993795A (en) | 1994-12-02 | 1996-06-19 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for prevention and/or treatment of no-mediated diseases |
SE9902765D0 (sv) | 1999-07-21 | 1999-07-21 | Astra Pharma Prod | Novel compounds |
CN1331326A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸 |
US20020090627A1 (en) | 2000-10-05 | 2002-07-11 | Rachel Meyers | 27419, a novel human arginine-N-methyl transferase and uses thereof |
DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
US7205304B2 (en) | 2002-03-13 | 2007-04-17 | Janssen Pharmaceutica N.V. | Sulfonyl-Derivatives as novel inhibitors of histone deacetylase |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
WO2004052862A1 (ja) | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
DE10315572A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazole |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
WO2004098634A2 (en) | 2003-04-30 | 2004-11-18 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Protein arginine n-methyltransferase 2 (prmt-2) |
US20050032794A1 (en) | 2003-08-05 | 2005-02-10 | Padia Janak K. | Diamine derivatives of quinone and uses thereof |
DE102004008807A1 (de) | 2004-02-20 | 2005-09-08 | Bayer Cropscience Ag | Pyrazolopyrimidine |
ME01601B (me) | 2004-03-15 | 2014-09-20 | Janssen Pharmaceutica Nv | Modulatori opioidnog receptora |
EP1784396B8 (en) | 2004-08-26 | 2011-04-20 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
WO2006025832A1 (en) | 2004-08-31 | 2006-03-09 | University Of North Carolina At Chapel Hill | Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
JP2008515950A (ja) | 2004-10-13 | 2008-05-15 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 泌尿器系障害の処置用の冷メントール受容体−1(cmr−1)アンタゴニストとしての4−置換ベンジルオキシ−フェニルメチルアミド誘導体 |
US9550990B2 (en) | 2004-12-10 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Regulation of epigenetic control of gene expression |
US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
US20090036435A1 (en) | 2005-01-21 | 2009-02-05 | Astex Therapeutics Limited | Pharmaceutical Compounds |
WO2006113458A1 (en) | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
ES2336142T3 (es) | 2005-08-19 | 2010-04-08 | Aventis Pharmaceuticals Inc. | Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo. |
EP1985620A4 (en) | 2006-02-07 | 2012-08-15 | Taisho Pharmaceutical Co Ltd | COMPOUND 10a-AZALIDE |
WO2007149782A2 (en) | 2006-06-23 | 2007-12-27 | University Of Medicine And Dentistry Of New Jersey | Selective inhibitors for transferases |
WO2008001076A1 (en) | 2006-06-26 | 2008-01-03 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
JP2009542809A (ja) * | 2006-07-12 | 2009-12-03 | メルク エンド カムパニー インコーポレーテッド | グレリン受容体アンタゴニストとしての置換ピラゾール |
JP2010503656A (ja) | 2006-09-13 | 2010-02-04 | アストラゼネカ アクチボラグ | スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用 |
UA95975C2 (ru) | 2006-09-15 | 2011-09-26 | Селджин Корпорэйшн | N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
US20080312298A1 (en) | 2007-04-11 | 2008-12-18 | Kenneth William Foreman | Methods for Identification of Modulators of Carm1 Methyl Transferase Activity |
WO2008137834A2 (en) | 2007-05-04 | 2008-11-13 | Osi Pharmaceuticals, Inc. | Crystal structure of smyd3 protein |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
US8133904B2 (en) | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
EP2226315A4 (en) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-AMINOQUINAZOLINE DERIVATIVE |
JP2009179616A (ja) | 2008-01-31 | 2009-08-13 | Kowa Co | 3−ナフチルピラゾール化合物 |
CN101981003B (zh) | 2008-02-29 | 2014-07-02 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
WO2009126537A1 (en) | 2008-04-07 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an hmt inhibitor |
JP5764822B2 (ja) | 2008-08-27 | 2015-08-19 | オンコセラピー・サイエンス株式会社 | がんの治療および診断の標的遺伝子としてのprmt1 |
AU2009295936B2 (en) | 2008-09-24 | 2014-07-17 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8323918B2 (en) | 2008-12-12 | 2012-12-04 | University Of South Carolina | Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases |
WO2010094009A2 (en) | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
US20130345268A1 (en) | 2009-02-13 | 2013-12-26 | The Trustees Of Dartmouth College | Methods and Compositions for the Treatment of RAS Associated Disorders |
EP2221053A1 (de) | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
EP2406262B1 (en) * | 2009-03-11 | 2016-02-17 | Auckland UniServices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
IN2012DN00352A (da) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
WO2011082098A1 (en) | 2009-12-30 | 2011-07-07 | The Rockefeller University | Lysine and arginine methyltransferase inhibitors for treating cancer |
US20130137748A1 (en) | 2010-02-03 | 2013-05-30 | Oncotherapy Science, Inc. | Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis |
WO2011096210A1 (en) | 2010-02-03 | 2011-08-11 | Oncotherapy Science, Inc. | Prmt1 and prmt6 for target genes of cancer therapy and diagnosis |
US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
ES2627085T3 (es) | 2010-05-07 | 2017-07-26 | Glaxosmithkline Llc | Indoles |
WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
HUE028977T2 (en) | 2010-09-10 | 2017-02-28 | Epizyme Inc | A method for determining the suitability of human EZH2 inhibitors during treatment |
WO2012060760A1 (en) | 2010-11-05 | 2012-05-10 | Fujirebio Diagnostics Ab | Molecular marker for cancer |
WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
US9029343B2 (en) | 2010-12-03 | 2015-05-12 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
US9394310B2 (en) | 2010-12-03 | 2016-07-19 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
AU2011336415B2 (en) | 2010-12-03 | 2016-08-11 | Epizyme, Inc. | Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes |
RU2013130253A (ru) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
AU2013265266A1 (en) | 2012-05-23 | 2015-01-15 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
PT2891492T (pt) | 2012-08-30 | 2022-12-13 | Univ Tokyo | Agente de controlo de endoparasitas |
CN104582696B (zh) | 2012-08-30 | 2018-07-03 | 国立大学法人东京大学 | 体内寄生虫防治剂及其使用方法 |
EP2935243B1 (en) | 2012-12-21 | 2018-03-14 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
CA2899363A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894230A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Methods of inhibiting prmt5 |
JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014178954A1 (en) | 2013-03-14 | 2014-11-06 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
EP2970136A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
KR102158756B1 (ko) * | 2013-03-14 | 2020-09-23 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
WO2014153090A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives asprmt1 inhibitors and uses thereof |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
EA201591532A1 (ru) | 2013-03-15 | 2016-03-31 | Эпизим, Инк. | Ингибиторы carm1 и их применение |
EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US20170291905A1 (en) | 2014-09-17 | 2017-10-12 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP3200588A4 (en) | 2014-09-17 | 2018-04-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
US20170283440A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2016044641A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016044604A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
JP2017527594A (ja) | 2014-09-17 | 2017-09-21 | エピザイム,インコーポレイティド | コアクチベーター関連アルギニンメチルトランスフェラーゼ1(carm1)阻害剤の塩、共結晶、非晶質形態、および結晶形態 |
WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
US20190083482A1 (en) | 2017-09-18 | 2019-03-21 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
-
2014
- 2014-03-14 KR KR1020197028270A patent/KR102158756B1/ko active IP Right Grant
- 2014-03-14 CA CA2903394A patent/CA2903394C/en active Active
- 2014-03-14 LT LTEP14717371.0T patent/LT2970132T/lt unknown
- 2014-03-14 MX MX2015012850A patent/MX2015012850A/es unknown
- 2014-03-14 HU HUE14717371A patent/HUE052926T2/hu unknown
- 2014-03-14 ES ES14717371T patent/ES2837034T3/es active Active
- 2014-03-14 SG SG11201506972PA patent/SG11201506972PA/en unknown
- 2014-03-14 US US14/775,794 patent/US9598374B2/en active Active
- 2014-03-14 WO PCT/US2014/029710 patent/WO2014153226A1/en active Application Filing
- 2014-03-14 PT PT147173710T patent/PT2970132T/pt unknown
- 2014-03-14 AU AU2014236146A patent/AU2014236146B2/en active Active
- 2014-03-14 KR KR1020157029130A patent/KR102028793B1/ko active Application Filing
- 2014-03-14 SI SI201431734T patent/SI2970132T1/sl unknown
- 2014-03-14 RS RS20201553A patent/RS61231B1/sr unknown
- 2014-03-14 DK DK14717371.0T patent/DK2970132T3/da active
- 2014-03-14 JP JP2016503202A patent/JP6581076B2/ja active Active
- 2014-03-14 EA EA201591531A patent/EA030481B1/ru unknown
- 2014-03-14 CN CN201480020631.8A patent/CN105339351B/zh active Active
- 2014-03-14 PL PL14717371T patent/PL2970132T3/pl unknown
- 2014-03-14 EP EP14717371.0A patent/EP2970132B1/en active Active
- 2014-03-14 CN CN201811160725.1A patent/CN109265400B/zh active Active
- 2014-03-14 BR BR112015022785A patent/BR112015022785A2/pt not_active Application Discontinuation
-
2015
- 2015-09-09 IL IL241368A patent/IL241368B/en active IP Right Grant
- 2015-10-07 ZA ZA2015/07441A patent/ZA201507441B/en unknown
-
2016
- 2016-07-05 HK HK16107817.8A patent/HK1219736A1/zh unknown
-
2017
- 2017-02-01 US US15/421,699 patent/US10081603B2/en active Active
-
2018
- 2018-05-02 AU AU2018203056A patent/AU2018203056B2/en active Active
- 2018-09-07 US US16/124,936 patent/US10800743B2/en active Active
-
2019
- 2019-07-21 IL IL268189A patent/IL268189B/en unknown
-
2020
- 2020-08-27 US US17/004,881 patent/US11512053B2/en active Active
- 2020-12-15 HR HRP20202008TT patent/HRP20202008T1/hr unknown
- 2020-12-17 CY CY20201101194T patent/CY1123637T1/el unknown
-
2023
- 2023-10-06 US US18/482,475 patent/US20240182426A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268189B (en) | Arginine methyltransferase inhibitors and their uses | |
IL267681A (en) | Selective grp94 inhibitors and their uses | |
HK1219947A1 (zh) | 抑製劑及其用途 | |
HK1220355A1 (zh) | 抑制劑和其用途 | |
HK1217410A1 (zh) | 抑制劑及其用途 | |
DK3043784T3 (da) | Arylethere og anvendelser deraf | |
DK3290407T3 (da) | Bromodomæneinhibitorer | |
AR095266A1 (es) | Inhibidores de bromodominios tetraciclicos | |
DK2968443T3 (da) | Hepcidinanaloger og anvendelser deraf | |
DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
DK3063144T3 (da) | Antiparasitære og pesticid-isoxazolinforbindelser | |
DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
DK3077467T3 (da) | Sikkativsammensætning og anvendelse deraf | |
DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
DK3060200T3 (da) | Tyrosinderivater og sammensætninger dermed | |
DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf | |
DK2941268T3 (da) | Selektive nox-1-inhibitor-peptider og anvendelser deraf | |
DK3066089T3 (da) | Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser | |
DK3068428T3 (da) | Annexin-ii-variant-sammensætninger og fremgangsmåder | |
FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
TH1501000566A (th) | ตัวยับยั้งนีพริไลซิน | |
TH1401007295A (th) | ตัวยับยั้งนีพริไลซิน | |
BR302013001196S1 (pt) | Configuração aplicada em pingente | |
BR302013001197S1 (pt) | Configuração aplicada em pingente |